Neuroinflammation, or chronic inflammation in the brain, has a crucial role in many devastating diseases, including Alzheimer’s, Multiple Sclerosis and many rare illnesses affecting brain function. An innovative drug that effectively targets neuroinflammation will profoundly benefit these patients as well as capture a large share of an estimated $45Bn market.
Reflection Therapeutics is developing targeted anti-inflammatory cell therapies to reduce neuroinflammation at key sites within a patients central nervous system. This will protect neurons and increase synaptic conectivity, which will prevent a decline in cognitive function. This therapy will be used to treat ALS and other devastating neurodegenerative diseases.